pulmicort neb- Children's Nebulizers - Suitable for Adults and Children with Asthma and Respiratory Diseases

pulmicort neb- Children's Nebulizers - Suitable for Adults and Children with Asthma and Respiratory Diseases - Portable Nebulizer Story

pulmicort neb

Pulmicort aerosol inhaler, commonly known as Budesonide, is an inhaled corticosteroid (ICS) commonly used to prevent and control asthma and other respiratory tract inflammations.


Core functions and principles
Anti-inflammatory control: Mainly by reducing swelling and inflammation in the airways of the lungs, making breathing easier.
Preventive treatment: These are "controller" medications that need to be used on a daily basis to prevent symptoms. It is not used to relieve acute asthma attacks.
Primary Indication: FDA-approved for the maintenance treatment of asthma in children 12 months to 8 years of age. In addition, it is also commonly used clinically to treat laryngitis (croup) in infants and young children.
How to use and precautions
Mode of administration: A jet nebulizer must be used. The use of ultrasonic nebulizers is strictly prohibited as the latter may render the medication ineffective.
Daily care: After atomization, be sure to rinse your mouth and spit out the remaining liquid to prevent oral fungal infection (thrush). If you use a mask for inhalation, you should wash your face after completion to prevent hormone irritation of the skin.
Onset of effects: Symptom improvement is usually seen after 2-8 days of use, but maximum benefit may take 4-6 weeks.
Mixing Contraindications: Primic should not be mixed with other nebulized medications unless specifically directed by your doctor.
Common side effects
Local: Oral candida infection (thrush), hoarseness, throat irritation, or cough.
Systemic: Long-term use of high doses may affect children's growth rate, cause bone density loss, or increase intraocular pressure (cataracts/glaucoma).
Are you inquiring about a specific starting dose for a child or need to know about nebulizer hardware compatibility?

0 comments

Leave a comment